CHM 1301 / Chimeric Therap, Case Western Reserve University - LARVOL DELTA

Chimeric Therapeutics provides additional information on vitro data for CHM 1301 (BiotechDispatch) - "Cell therapy company Chimeric Therapeutics...has provided additional information on its previously announced positive in vitro data for CHM 1301...CHM 1301 is a next-generation chlorotoxin (CLTX) chimeric antigen receptor (CAR) NK cell therapy...CHM 1301 was studied in preclinical in vitro human ovarian and pancreatic cancer models, demonstrating highly promising efficacy, said the company...In ovarian cancer, cell killing was increased up to 260 per cent as compared to first-generation CHM 0201 cells, while in pancreatic cancer, cell killing was increased up to 300 per cent as compared to first-generation CHM 0201 cells."

Preclinical • Gastrointestinal Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor

Chimeric Therapeutics announces positive preclinical data for CHM 1301 (The Market Herald) - "Chimeric Therapeutics...has announced positive in vitro data for CHM 1301, the company’s next-generation chlorotoxin (CLTX) chimeric antigen receptor (CAR) NK cell therapy program....CHM 1301 was studied in pre-clinical in vitro models of human ovarian cancer and pancreatic cancer, where it demonstrated significant efficacy in killing cancer cells.The drug increased cell killing in ovarian cancer by around 260 per cent, compared to first-generation CHM 0201 cells, and in pancreatic cancer, cell killing increased by 300 per cent....Based on this success, Chimeric is advancing the CHM 1301 program to its next stage of preclinical development, with the help of its recently developed armoured NK cell platform (CHM 0301)."

Preclinical • Gastrointestinal Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor

Chimeric Therapeutics receives patent protection in India for CLTX CAR technology, allowance notice in Israel (Proactiveinvestors) - "Chimeric Therapeutics Ltd...is moving swiftly in the quest to expand its CLTX CAR intellectual property portfolio, with the receipt of a patent grant from India and a notice of allowance from Israel. The India patent covers certain applications of chimeric antigen receptor (CAR) technology using chlorotoxin (CLTX), including Chimeric’s clinical-stage CAR T asset CHM 1101 and pre-clinical stage CAR NK asset CHM 1301....The India patent has been granted under patent number IN 424963, while the Official Notification Prior to Acceptance from the Israel Patent Office is for application IL 258670. Chimeric Therapeutics, the only ASX-listed clinical stage cell therapy company, holds the exclusive worldwide licence to develop and commercialise IN 424963, IL 258670, and related patent applications filed in other global territories."

Patent • Oncology • Solid Tumor